Central Research Institute inaugurated the Current Good Manufacturing Practise compliant facility in dist. Solan, Himachal Pradesh.

May 3, 2016

Drugs and Pharmaceuticals

Status: Commissioned

Promoter: Central Research Institute (CRI)

Project: Inaugurated the Current Good Manufacturing Practise (CGMP) compliant facility

Location: CRI, Kasauli, dist. Solan, Himachal Pradesh

Project Details: The institute was inaugurated on 24th April, 2016. The facility will be for the manufacture of DPT and TT vaccine. TT vaccine has been commercialized from this facility for Universal Immunization Programme use and production of DPT bulk has been initiated. CRI is exploring the feasibility of establishing WHO prequalified cGMP compliant manufacturing facility for yellow fever vaccine. This will enable the institute to supply yellow fever vaccine to African and Latin American countries. The institute has plans to manufacture all vaccines viz., Japanese encephalitis vaccine, rabies vaccine and typhoid vaccine, which were earlier manufactured in the Institute, after establishing CGMP compliant facilities and application of recent technological advancements. CRI plans to create state of the art, fully dedicated CGMP compliant laboratory for research on vaccine development and various other public health related issues. The institute plans to undertake research on newer vaccine candidates for existing and emerging diseases and to manufacture more efficacious and safer vaccines. CRI is in process of acquiring 128 bighas of land from Himachal Pradesh Government for creation of CGMP compliant facility for manufacturing of therapeutic anti-sera. CRI has started apprenticeship training for maintenance of high end machinery and equipment that have been installed with creation of new cGMP facility for production of DPT vaccine in the institute. The institute is involved in manufacture and supply of various lifesaving therapeutic antisera for snake bites, rabies and diphtheria, and supplies yellow fever vaccine to different parts of the country. Diagnostic reagents such as diagnostic antigens for typhoid, typhus fever and brucellosis and diagnostic antisera for cholera and salmonella are also manufactured and supplied to various institutions.

Somu Chemicals And Pharmaceuticals has commissioned a herbal extract and API manufacturing unit in Karnataka

April 5, 2016

Drugs and Pharma

Status: Commissioned

Promoter: Somu Chemicals And Pharmaceuticals, a part of Somu Group

Project: Commissioned a 65,000 kgs/ yr herbal extract and active pharmaceutical ingredient manufacturing unit

Location: Anekal Taluka, dist. Bengaluru, Karnataka

Project Details: The project is spread over on 10,000 sq. ft. The estimated cost of the project is Rs. 34.2 million. Commercial production commenced in February 2016. According to MoEF sources, the products include 14,000 kgs/ yr herbal extracts, 51,000 kgs/ yr cosmetics ingredients, nutraceutical ingredients, pharma intermediates and API with R&D activity. Effluent generated will be treated in common effluent treatment plant. The total power requirement of the industry is 65 kVA. Greenbelt will be developed in 30% of the total area.

Nakoda Chemicals is planning an expansion of its bulk drug manufacturing unit in dist. Rangareddy, Telangana.

December 5, 2015

Drugs and Pharmaceuticals

Status: Planning Stage

Promter: Nakoda Chemicals

Planning an expansion of its bulk drug manufacturing unit from its existing capacity of 34.2 TPA to 141.16 TPA.

Location: IDA Jeedimetla, dist. Rangareddy, Telangana

Current Status: The project is waiting for environmental clearance.

Parenteral Drugs (India) is relocating its drugs manufacturing unit from dist. Indore to dist. Khargone, Madhya Pradesh.

December 5, 2015

Drugs and Pharmaceuticals

Status: Under Implementation

Promoter: Parenteral Drugs (India)

Project: Relocation of drugs manufacturing unit.

Project Details: The plant is being relocated from Village Asrawad, Post Dudhia, Nemawar Road, dist. Indore to Village Panwa, Tehsil Kasrawad, dist. Khargone. The company has initiated the process of relocation of the plant in April 2015 and for the purpose of relocation of the same, since, the civil work has almost been completed for its IV Fluids and allied manufacturing activities, the company has discontinued its manufacturing operations at Village Asrawad with effect from 24th August, 2015.

Mankind Pharma is planning a pharmaceuticals & food formulations manufacturing unit in Sikkim.

November 18, 2015

Durgs and Pharmaceuticals

Status: Conceptual Stage

Promoter: Mankind Pharma

Project: Plans a pharmaceuticals & food formulations manufacturing unit

Location: Sikkim

Project Details: The project is in initial stage of planning.

Jayasaketh Chemicals is planning an expansion of its bulk drugs manufacturing unit in dist. Ballari, Karnataka.

November 12, 2015

Drugs and Pharma

Status: Planning Stage

Promoter: Jayasaketh Chemicals

Project: Planning capacity expansion of existing bulk drugs manufacturing unit

Location: Mundrigi Industrial Area, dist. Ballari, Karnataka

Project Details: The capacity to be augmented from existing 800 TPA to 1,500 TPA.

Equipment Supplier: Venus Industrial Equipments is the equipment supplier.

The project is awaiting environmental clearance. Work on the project is expected to commence after receiving the clearance.

Lewens labs is planning a bulk drug manufacturing unit in dist. Bharuch, Gujarat.

November 12, 2015

Drugs and Pharma

Status: Planning Stage

Promoter: Lewens labs

Project: Plans a 32.36 TPM bulk drug manufacturing unit

Project Location: Dahej, dist. Bharuch, Gujarat

Project Details: The project will spread over 10,000 sq. mtrs. Civil contractor has been appointed. Equipment supplier is yet to be appointed. The cost of the project is Rs. 100 million. Work on the project will commence in December 2015. According to MoEF sources, the company has proposed 3,000 sq. mtrs area for green belt development. Industrial waste water will be treated in Primary, Secondary & Tertiary treatment plant.


Get every new post delivered to your Inbox.

Join 3,647 other followers